Expanded Access Programm BIBW 2992 for NSCLC Last Line Treatment.
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2016
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Expanded access; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 09 Nov 2016 Status changed from recruiting to completed.
- 02 Oct 2010 New trial record